Novartis AG (NVSEF)
134.53
+0.33
(+0.25%)
USD |
OTCM |
Oct 05, 16:00
Novartis Gross Profit Margin (Quarterly) : 74.47% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 74.47% |
| March 31, 2026 | 73.78% |
| December 31, 2025 | 73.44% |
| September 30, 2025 | 74.58% |
| June 30, 2025 | 76.38% |
| March 31, 2025 | 75.10% |
| December 31, 2024 | 74.73% |
| September 30, 2024 | 74.23% |
| June 30, 2024 | 74.29% |
| March 31, 2024 | 73.54% |
| December 31, 2023 | 73.16% |
| September 30, 2023 | 72.11% |
| June 30, 2023 | 70.78% |
| March 31, 2023 | 72.30% |
| December 31, 2022 | 72.72% |
| September 30, 2022 | 72.61% |
| June 30, 2022 | 70.65% |
| March 31, 2022 | 69.23% |
| December 31, 2021 | 69.95% |
| September 30, 2021 | 69.91% |
| June 30, 2021 | 69.79% |
| March 31, 2021 | 67.46% |
| December 31, 2020 | 66.98% |
| September 30, 2020 | 69.39% |
| June 30, 2020 | 69.78% |
| Date | Value |
|---|---|
| March 31, 2020 | 69.70% |
| December 31, 2019 | 67.81% |
| September 30, 2019 | 68.98% |
| June 30, 2019 | 71.05% |
| March 31, 2019 | 70.87% |
| December 31, 2018 | 64.89% |
| September 30, 2018 | 68.64% |
| June 30, 2018 | 68.68% |
| March 31, 2018 | 68.42% |
| December 31, 2017 | 65.24% |
| September 30, 2017 | 65.17% |
| June 30, 2017 | 65.22% |
| March 31, 2017 | 64.42% |
| December 31, 2016 | 63.57% |
| September 30, 2016 | 63.98% |
| June 30, 2016 | 64.31% |
| March 31, 2016 | 63.69% |
| December 31, 2015 | 63.67% |
| September 30, 2015 | 64.22% |
| June 30, 2015 | 64.65% |
| March 31, 2015 | 66.73% |
| December 31, 2014 | 66.37% |
| September 30, 2014 | 66.11% |
| June 30, 2014 | 67.36% |
| March 31, 2014 | 66.32% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Roche Holding AG | -- |
| Addex Therapeutics Ltd. | -153.2% |
| Oculis Holding AG | -- |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 29.75% |
| Return on Assets | 11.22% |
| Return on Invested Capital | 15.53% |
| Profit Margin (Quarterly) | 22.61% |
| Operating Margin (Quarterly) | 32.84% |
| Return on Net Operating Assets | 14.50% |